Bionano Genomics Dirección

Dirección controles de criterios 3/4

El CEO de Bionano Genomics' es Robert Holmlin , nombrado en Jan 2011, tiene una permanencia de 13.25 años. compensación anual total es $2.77M, compuesta por 19.7% salario y 80.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de MX$826.42K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 4.9 años, respectivamente.

Información clave

Robert Holmlin

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	47.7%
Permanencia del CEO	13.3yrs
Participación del CEO	0.09%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Robert Holmlin en comparación con los beneficios de Bionano Genomics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$599k	-US$232m
Sep 30 2023	n/a	n/a	-US$227m
Jun 30 2023	n/a	n/a	-US$147m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$3m	US$544k	-US$133m
Sep 30 2022	n/a	n/a	-US$117m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	US$8m	US$484k	-US$72m
Sep 30 2021	n/a	n/a	-US$61m
Jun 30 2021	n/a	n/a	-US$51m
Mar 31 2021	n/a	n/a	-US$41m
Dec 31 2020	US$708k	US$376k	-US$41m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$899k	US$404k	-US$30m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$3m	US$390k	-US$18m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$605k	US$379k	-US$23m

Compensación vs. Mercado: La compensación total de Robert($USD2.77M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD197.06K).

Compensación vs. Ingresos: La compensación de Robert ha sido consistente con los resultados de la empresa en el último año.

CEO

Robert Holmlin (55 yo)

13.3yrs

Permanencia

US$1,254,658

Compensación

Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and served as its Secretary. D...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Holmlin	President	13.3yrs	US$1.25m	0.094% $ 1.0m
Mark Oldakowski	Chief Operating Officer	6.5yrs	US$884.78k	0.061% $ 657.1k
Alka Chaubey	Chief Medical Officer	3.8yrs	US$864.78k	0.047% $ 509.1k
Gulsen Kama	Chief Financial Officer	less than a year	sin datos	sin datos
Mark Adamchak	VP of Accounting & Controller	5.9yrs	sin datos	sin datos
Jonathan Dixon	General Counsel & Secretary	2.2yrs	sin datos	0.0053% $ 57.0k
Stanislas Marin	Vice President of Global Sales	2.3yrs	sin datos	sin datos
Donna Polizio	Global Head of Market Access	1.5yrs	sin datos	sin datos
Cory Kreeck	Global Head of People Operations	2.3yrs	sin datos	sin datos
Klint Rose	Head of Research & Development	less than a year	sin datos	sin datos

2.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BNGO * se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Holmlin	President	13.3yrs	US$1.25m	0.094% $ 1.0m
Christopher Twomey	Independent Director	5.8yrs	US$72.75k	0.0097% $ 104.3k
David Barker	Independent Chairman of the Board	14yrs	US$97.75k	0.0087% $ 94.4k
Albert Luderer	Independent Director	12.6yrs	US$77.75k	0% $ 0
Hannah Mamuszka	Independent Director	4yrs	US$60.25k	0.0098% $ 106.4k
Kristiina Vuori	Independent Director	5yrs	US$70.25k	0% $ 0
Yvonne Linney	Independent Director	4yrs	US$57.75k	0% $ 0
Vincent Wong	Independent Director	2.4yrs	US$62.75k	0% $ 0
Aleksandar Rajkovic	Independent Director	2.3yrs	US$57.75k	0% $ 0

5.0yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de BNGO * se considera experimentada (4.9 años de antigüedad promedio).

Bionano Genomics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. Announces Executive Changes

Independent Director recently bought Mex$862k worth of stock

Chief Financial Officer recently bought Mex$589k worth of stock

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Recent updates

Bionano Genomics, Inc., Annual General Meeting, Jun 18, 2024

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Genomics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000002 million.

Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics

Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting

Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$6.81 loss per share (vs US$4.59 loss in FY 2022)

Bionano Genomics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bionano Genomics, Inc. announced that it has received $35 million in funding

Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

Bionano Announces Full Commercial Release of the Stratys™? System for High Throughput Optical Genome Mapping

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing

Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via™ Software for Ogm Data Analysis in Constitution Genetic Disease Research

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

Third quarter 2023 earnings released

Bionano Genomics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Bionano Genomics, Inc. announced that it expects to receive $35 million in funding

New minor risk - Market cap size

Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease

Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Bionano Genomics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.24 loss per share (vs US$1.13 loss in 2Q 2022)

Bionano Genomics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Bionano Genomics, Inc. Announces the Stratys System for OGM and VIA™? Software for Hematologic Malignancies

Bionano Genomics, Inc.(NasdaqCM:BNGO) dropped from Russell Small Cap Comp Value Index

Bionano Genomics, Inc. Announces Peer-Reviewed Publication on the Utility of Combining Ogm and A 523-Gene Ngs Panel for Standard Evaluation of Myeloid Cancers

Independent Director recently bought Mex$862k worth of stock

Bionano Announces Commercial Release of New Kits for Its Ionic System Featuring New Chemistry for Nucleic Acid Extraction from Ffpe and Tumor Tissue

Bionano Genomics Receives Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price Requirement

Chief Financial Officer recently bought Mex$589k worth of stock

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.10 loss in 1Q 2022)

Bionano Genomics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.26 loss in FY 2021)

Bionano Genomics, Inc. Launches Next-Generation Versions of Its Reagent Kits and Chip Consumable, Along with Updates to Its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Bionano Genomics, Inc. Announces Publication of Study Utilizing Optical Genome Mapping

Bionano Genomics, Inc. Announces Resignation of Richard Shippy as Chief Business Officer

Bionano Genomics, Inc. Appoints Donna Polizio as Global Head of Market Access

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.074 loss in 3Q 2021)

Bionano Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Bionano Genomics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Hamilton and Bionano Genomics, Inc. Announce Commercial Availability of World's First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing That WGS Identified Only 63% of Structural Variations That OGM Detected in Liver Cancer

Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories

Bionano Genomics, Inc. Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss

Bionano Genomics Announces Publication of Study Demonstrating Utility of OGM as Part of Comprehensive Workflow for Quality Evaluation of Human Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity

Bionano Genomics Announces First Publication Using Ogm for Detection of Repeat Expansions in Canvas and Adult-Onset Ataxia

Bionano Genomics, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.067 loss in 2Q 2021)

Bionano Genomics, Inc. Announces Publication of Research Study in Myelodysplastic Syndrome

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Chromosome Instability During Culture of Induced Pluripotent Stem Cells

Bionano Genomics, Inc. Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders

Bionano Genomics, Inc. Reports First Published Study of OGM in Pediatric AML Shows OGM Identifies MRD Markers and Other Novel Variants That Can Impact Case Management

Independent Chairman of the Board recently bought Mex$321k worth of stock

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.038 loss in 1Q 2021)

High number of new directors

Bionano Genomics, Inc. Announces Release of Version 6.2 of Its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

Bionano Genomics Announces Publication of A New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-Cell Acute Lymphoblastic Leukemia

High number of new directors

Bionano Genomics, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

High number of new directors

Bionano Genomics, Inc. Appoints Aleksandar Rajkovic as Class III Director

Bionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis

Bionano Genomics, Inc. Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers